A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.
about
Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategiesPlasmodium cysteine repeat modular proteins 1-4: complex proteins with roles throughout the malaria parasite life cycleA multidomain adhesion protein family expressed in Plasmodium falciparum is essential for transmission to the mosquitoMalaria Parasites: The Great EscapeShuffled domains in extracellular proteinsA viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityStein and Moore Award address. Reconstructing history with amino acid sequencesThe S. aureus 4-oxalocrotonate tautomerase SAR1376 enhances immune responses when fused to several antigens.The chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferencesProtein export marks the early phase of gametocytogenesis of the human malaria parasite Plasmodium falciparumIdentification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium bergheiTwo nucleus-localized CDK-like kinases with crucial roles for malaria parasite erythrocytic replication are involved in phosphorylation of splicing factorThe Puf-family RNA-binding protein PfPuf2 regulates sexual development and sex differentiation in the malaria parasite Plasmodium falciparumDevelopmental arrest of the human malaria parasite Plasmodium falciparum within the mosquito midgut via CTRP gene disruptionUtilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria.Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodiesProtective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity.Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigensHelminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in miceNanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.Genome-wide identification of molecular mimicry candidates in parasites.Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum.Isolation and functional characterization of two distinct sexual-stage-specific promoters of the human malaria parasite Plasmodium falciparumThe IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodiesA protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains.Micronemal transport of Plasmodium ookinete chitinases to the electron-dense area of the apical complex for extracellular secretionAntibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparumEpidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationPotential immune mechanisms associated with anemia in Plasmodium vivax malaria: a puzzling questionDevelopment of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.In vitro generation of Plasmodium falciparum ookinetes.Gene flow and biological conflict systems in the origin and evolution of eukaryotes.Current developments in malaria transmission-blocking vaccines.
P2860
Q24805493-D2EBF26C-83EE-4A2A-A09A-677E2CB19809Q27973462-7868D569-AD04-407D-A707-43263B05230CQ27974391-E4AE8E1C-AAF8-44D6-B349-F2A632C21CA6Q27974493-9C404C17-6264-4E11-B741-97F7F5D42A92Q28080325-72DBA8CC-4E43-47EA-B092-1F8C8278ED48Q28288029-7AA9F8E2-0D84-423C-A7C2-4619CB5800FEQ28740771-322F038B-A46A-4002-8B12-915579AF36F1Q28756240-423B60C6-DF44-4117-9983-A178CB30C9F2Q29994694-5CC7E244-912B-4B3A-B049-31D1F323F390Q30041470-2BE9589B-16A7-48A1-AC2A-3D8DC0208033Q30042317-DAE31FCD-F2F9-4B5D-A808-98D5E743A1F5Q30043378-AEB37DD8-027B-4D40-8740-D090BEBA9BF1Q30043596-146581BF-5625-44D0-B4B6-6D5899720736Q30043858-55E30DE3-5D34-403D-BE69-013B8BA028E4Q30046847-C26BF089-3483-4500-874E-FE8A6A7E9EC5Q30243982-6B45377E-A289-4712-9388-E50E4B7B81EEQ30832639-FEA43F20-7144-4D80-AF9F-8009BD05D045Q31903270-21125753-2CDB-456A-BAA3-66E8BD582233Q33591209-831482C4-6DAC-44E5-923F-76DBC7140271Q33596771-4C2D7E33-2D5E-4D99-9CD5-1FC63751B0A7Q33747301-C8A0F664-2FD6-4817-B0AA-BB51CD92B8D6Q33756304-68CE183E-C296-4013-AEB3-1F6CB797CA05Q33759135-2A2BE50C-6161-4411-A414-722FD9A4A0E3Q33812439-9595B98A-114C-44DE-A39F-888F451F56B3Q33847600-2608B799-238F-44E0-9B40-2136ED631886Q33866574-8BF781DE-EE0C-40E4-BD5B-8D17D6604E8FQ33868257-235E05AC-CBDD-4FCC-BD91-FC16E8C8469BQ33892507-74E8F969-CD0F-4697-9988-78BAC047D69BQ34000822-2D90EEED-5974-47C2-8944-C760A1A9F121Q34004960-7391E625-C87F-49F2-AD53-48D8D2F863E5Q34005064-4B9B1A15-9C16-4AAA-87DB-508F993450EAQ34005142-D172906E-B21A-4DF0-885E-84EAEC6725B3Q34045009-FD13AF33-D93B-4033-839B-61A91C70F3E9Q34111897-68005E6A-4F4F-4488-9BEC-5DBC140E24B6Q34177472-22BEB3A2-5C33-42C4-AD59-DACBEE8D358FQ34298686-CB96D299-FF43-4494-9E4D-05880FDF9658Q34341570-64F15CA1-4B78-49FA-9CE5-4AD611148850Q34341749-6C190665-6196-4D6B-A2BB-08158DC0DC21Q34392545-6A40876E-8652-4763-BA88-892E4A64F95BQ34451883-51983D3B-A849-4377-A7A0-15B820DE3157
P2860
A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
A vaccine candidate from the s ...... hat contains EGF-like domains.
@en
A vaccine candidate from the s ...... hat contains EGF-like domains.
@nl
type
label
A vaccine candidate from the s ...... hat contains EGF-like domains.
@en
A vaccine candidate from the s ...... hat contains EGF-like domains.
@nl
prefLabel
A vaccine candidate from the s ...... hat contains EGF-like domains.
@en
A vaccine candidate from the s ...... hat contains EGF-like domains.
@nl
P2093
P356
P1433
P1476
A vaccine candidate from the s ...... hat contains EGF-like domains.
@en
P2093
Coligan JE
Keister DB
McCutchan TF
P2888
P356
10.1038/333074A0
P407
P577
1988-05-01T00:00:00Z
P6179
1009575366